Surprisingly, they showed that anti-TIGIT mAb could reduce tumor mass and slow tumor growth in T cell-deficient mice; in addition, NK cell deficiency resulted in an increased metastasis and number of exhausted CD8+ T cells, and abolished the effect of TIGIT blockade even in the presence of TIGIT-expressing CD8+ T cells (13). The gene discussed is CD8A; the disease is neoplasm.